Comparative Pharmacology
Head-to-head clinical analysis: FOCALIN versus METHYLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOCALIN versus METHYLIN.
FOCALIN vs METHYLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexmethylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations. The d-threo enantiomer of methylphenidate is responsible for the therapeutic activity.
Methylphenidate is a central nervous system stimulant. It blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Initial 2.5-5 mg orally twice daily, increase by 2.5-10 mg/day weekly; max 20 mg twice daily.
10 mg orally twice daily, administered 4-6 hours apart; doses may be adjusted in 5-10 mg increments weekly up to 60 mg/day.
None Documented
None Documented
2-3 hours in children and adults; 4-5 hours in adolescents (due to slower metabolism). Clinical context: t1/2 supports twice-daily dosing (immediate-release) for continuous therapeutic effect
2-4 hours (short elimination half-life, requiring multiple daily dosing; immediate-release: 3-4 hours, extended-release: 3-6 hours)
Renal: 80% (approximately 50% as unchanged drug, 30% as metabolites); Fecal: negligible
Renal: 90% (mainly as metabolites, 30-50% as unchanged drug); fecal: <1%
Category C
Category C
CNS Stimulant
CNS Stimulant